Lamivudina + Zidovudina Farmoz (Zidovudine, Lamivudine)

Zidovudine is a nucleoside reverse transcriptase inhibitor. Inside infected cells it is converted to its active triphosphate form, which competes with natural nucleotides for incorporation into viral DNA. This results in chain termination, blocking HIV reverse transcriptase and preventing viral replication.

The specific dose of Lamivudina + Zidovudina is determined by the prescribing clinician based on the patient’s age, weight, renal function, and treatment guidelines. Healthcare professionals should follow local prescribing information and adjust the regimen as needed.

Safety in pregnancy and lactation has not been definitively established. Clinicians should evaluate the potential benefits against possible risks to the fetus or infant. If treatment is essential, it may be continued under close medical supervision, following national guidelines.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudina + Zidovudina combines two nucleoside reverse transcriptase inhibitors, offering a dual mechanism that can simplify regimens compared with using each drug separately. Compared with newer agents, it may have a different side‑effect profile and drug‑interaction potential, which clinicians consider when selecting therapy.

The product should be stored at room temperature, below 25 °C, in its original packaging. It must be kept away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Lamivudina + Zidovudina is administered orally, typically as a tablet taken with or without food. The exact administration schedule is prescribed by the treating physician and should be followed precisely to ensure optimal therapeutic effect.

Serious risks include severe lactic acidosis, hepatic steatosis, profound anemia, neutropenia, hypersensitivity reactions and pancreatitis. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Individuals with known hypersensitivity to zidovudine, lamivudine, or any excipients in the formulation should avoid this product. Additionally, patients with severe bone marrow suppression or uncontrolled liver disease may be contraindicated, pending clinical assessment.